fda compounding semaglutide enforcement october 2025 news is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified Compounded Semaglutide: Safety & Regulation

Pharmacological Treatment and Time from MBS to Diagnosis of PBH The median time to diagnosis of PBH (time interval between MBS and PBH diagnosis) of all patients was 25 months (2 years and 1 month)

While this does not constitute clinical evidence, it suggests measurable inflammatory changes that extend beyond subjective symptom reporting

At Ness, we partner only with trusted, licensed U.S

Weve never had a recall, but if we ever did, ShipBob has us covered in terms of compliance

The procedure is generally quick and well-tolerated by most individuals

What differs is the upstream context: before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights including FTO, GLP1R, MC4R, and TCF7L2 so a subscription decision starts from your baseline biology, not guesswork